Cleared Traditional

K973203 - THYMOSTAT ELISA FOR THE DETECTION OF HU...

K973203 is an FDA 510(k) clearance for THYMOSTAT ELISA FOR THE DETECTION OF HU..., manufactured by Sangstat Medical Corp.. The device is a Class 2 Immunology device with product code DAK cleared through the Traditional 510(k) pathway after a 400-day FDA review.

K973203 · Sangstat Medical Corp. · Immunology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Sep 1998
Decision
400d
Days
Class 2
Risk

K973203 is an FDA 510(k) clearance for the THYMOSTAT ELISA FOR THE DETECTION OF HUMAN IGG,M AND A ANTI-RABBIT IGG ANTIB.... Classified as Complement C1q, Antigen, Antiserum, Control (product code DAK), Class II - Special Controls.

Submitted by Sangstat Medical Corp. (Menlo Park, US). The FDA issued a Cleared decision on September 30, 1998 after a review of 400 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 866.5240 - the FDA immunology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Elevated predicate reliance profile. This clearance follows a standard predicate-based equivalence path within the Immunology review framework, consistent with the majority of Class II 510(k) submissions.

View all Sangstat Medical Corp. devices

FDA 510(k) Submission Details - K973203

510(k) Number K973203 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received August 26, 1997
Decision Date September 30, 1998
Days to Decision 400 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary Statement
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
296d slower than avg
Panel avg: 104d · This submission: 400d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

DAK Device Classification - Class 2, Special Controls

Product Code DAK Complement C1q, Antigen, Antiserum, Control
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.5240
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Immunology devices follow this clearance model.

Regulatory Peers - DAK Complement C1q, Antigen, Antiserum, Control

All 15
Devices cleared under the same product code (DAK) and FDA review panel - the closest regulatory comparables to K973203.
BINDAZYME CLQ CIC EIA KIT
K031563 · The Binding Site, Ltd. · Sep 2003
CIC-C1Q EIA
K012576 · American Laboratory Products Co., Ltd. · Jan 2002
HUMAN C1Q RADIAL IMMUNODIFFUSION KIT
K951968 · Kent Laboratories, Inc. · May 1995
C1 RID KIT
K914388 · The Binding Site, Ltd. · Oct 1991
IC MICROASSAY
K864312 · Diamedix Corp. · Jan 1987
CORDIA IC
K844294 · Cordis Corp. · Feb 1985